{"schema_version":"secwatch.filing_event.v1","accession":"0001619856-24-000018","form_type":"8-K","ticker":"CRBU","cik":"0001619856","company_name":"Caribou Biosciences, Inc.","filed_at":"2024-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.279597+00:00","generated_at":"2026-06-04T02:19:40.201092+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Caribou Biosciences receives FDA IND clearance for CB-010 in lupus; GALLOP Ph1 trial expected by YE 2024","bullets":["FDA cleared IND for CB-010 (allogeneic anti-CD19 CAR-T) to treat lupus nephritis and extrarenal lupus.","Phase 1 GALLOP trial expected to initiate by year-end 2024; evaluates safety of single infusion with partial HLA matching.","CB-010 clinical development expanded from oncology to autoimmune diseases; driven by encouraging initial ANTLER trial data in r/r B-NHL.","Caribou reports $372.4M cash as of Dec 31, 2023, expected to fund operations into Q1 2026.","Initial dose expansion data from ANTLER Phase 1 trial for 2L LBCL to be presented at a medical congress in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001619856-24-000018","json":"https://secwatch.observer/filing/0001619856-24-000018.json","markdown":"https://secwatch.observer/filing/0001619856-24-000018.md","text":"https://secwatch.observer/filing/0001619856-24-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000018/0001619856-24-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1619856/000161985624000018/crbu-20240404.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T02:19:40.201092+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}